Hikma Pharmaceuticals (HIK) Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
HIK Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£12.09 |
| 52 Week High | UK£21.64 |
| 52 Week Low | UK£11.87 |
| Beta | 0.65 |
| 1 Month Change | -22.00% |
| 3 Month Change | -20.25% |
| 1 Year Change | -40.03% |
| 3 Year Change | -30.58% |
| 5 Year Change | -45.22% |
| Change since IPO | 328.72% |
Recent News & Updates
Recent updates
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops, manufactures, and supplies branded, generic, and injectable medicines across MENA, Europe, and North America. What are the underlying business or industry changes driving this perspective?Market Cool On Hikma Pharmaceuticals PLC's (LON:HIK) Earnings
Dec 01
Hikma Pharmaceuticals (LON:HIK) Has A Somewhat Strained Balance Sheet
Oct 27Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
Sep 10Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)
Aug 02Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Jun 19Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects
Apr 08Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Mar 17
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Shareholder Returns
| HIK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.08% | -2.5% | -1.2% |
| 1Y | -40.0% | 19.7% | 21.0% |
Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 19.7% over the past year.
Return vs Market: HIK underperformed the UK Market which returned 21% over the past year.
Price Volatility
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: HIK has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HIK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,400 | Said Samih Darwazah | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| HIK fundamental statistics | |
|---|---|
| Market cap | UK£2.65b |
| Earnings (TTM) | UK£301.18m |
| Revenue (TTM) | UK£2.51b |
Is HIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIK income statement (TTM) | |
|---|---|
| Revenue | US$3.35b |
| Cost of Revenue | US$1.91b |
| Gross Profit | US$1.44b |
| Other Expenses | US$1.04b |
| Earnings | US$402.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.83 |
| Gross Margin | 43.03% |
| Net Profit Margin | 12.00% |
| Debt/Equity Ratio | 59.5% |
How did HIK perform over the long term?
See historical performance and comparisonDividends
Does HIK pay a reliable dividends?
See HIK dividend history and benchmarks| Hikma Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Mar 19 2026 |
| Dividend Pay Date | Apr 30 2026 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 48 days |
Does HIK pay a reliable dividends?
See HIK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 00:48 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| James Gordon | Barclays |
| Beatrice Fairbairn | Berenberg |